Clinically relevant interpretation of genotype for resistance to abacavir-Reference-Cited by-同舟云学术

Clinically relevant interpretation of genotype for resistance to abacavir

Published:2003-08 Issue:12 Volume:17 Page:1795-1802
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Brun-Vézinet Françoise,Descamps Diane,Ruffault Annick,Masquelier Bernard,Calvez Vincent,Peytavin Gilles,Telles Fabienne,Morand-Joubert Laurence,Meynard Jean-Luc,Vray Muriel,Costagliola Dominique

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference19 articles.

1. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

2. A Novel Genotype Encoding a Single Amino Acid Insertion and Five Other Substitutions Between Residues 64 and 74 of the HIV-1 Reverse Transcriptase Confers High-Level Cross-Resistance to Nucleoside Reverse Transcriptase Inhibitors

3. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir

4. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

5. Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction and molecular field view of drug resistance in HIV-1 protease mutants;Scientific Reports;2022-02-21

2. An Innovative Sequence-to-Structure-Based Approach to Drug Resistance Interpretation and Prediction: The Use of Molecular Interaction Fields to Detect HIV-1 Protease Binding-Site Dissimilarities;Frontiers in Chemistry;2020-04-29

3. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients;Journal of Antimicrobial Chemotherapy;2020-02-17

4. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors;Antimicrobial Agents and Chemotherapy;2019-08

5. An evolutionary-based approach to quantify the genetic barrier to drug resistance in fast-evolving viruses: an application to HIV-1 subtypes and integrase inhibitors;2019-05-24